



## **Precision BioSciences Receives National Cancer Institute Grant to Develop Blood Cancer Therapeutic**

**RESEARCH TRIANGLE PARK, North Carolina, Mar. 20, 2008** - Precision BioSciences, Inc. today announced that it has been awarded a Phase I SBIR grant from the National Cancer Institute. The award will enable the company to initiate preclinical research into a blood cancer therapeutic utilizing the firm's Directed Nuclease Editor (DNE) technology. The company also intends to apply for a Phase II SBIR grant up on successful completion of the Phase I research.

"Our goal is to use the DNE technology to direct the correction of a gene responsible for several chronic myeloproliferative disorders, including essential thrombocythemia and polycythemia vera," said Precision BioSciences' Director of Cell Biology, Michael Nicholson. "If successful, this research will demonstrate a powerful new approach to the treatment of these blood cancers."

"This SBIR award, our second received in 2008, represents yet another important validation for Precision's industry-leading DNE technology," said Matthew Kane, Precision's CEO. "We are thrilled to have an opportunity to commence this project and are very appreciative of the support we have received from the National Cancer Institute."

### **About Precision BioSciences**

Precision's mission is to utilize its engineered endonuclease technology to become the world leader in the field of genomic molecular biology. Precision's proprietary *Directed Nuclease Editor*<sup>™</sup> (DNE) technology enables the production of genome editing enzymes that can be customized to modify essentially any gene in plant or animal cells.

Precision's unique approach is rapid and robust. With production time as short as two weeks, Precision BioSciences has already produced hundreds of custom endonucleases for partners and internal development that were designed to target naturally occurring sequences within genomes. Precision is focused on utilizing DNE technology to insert, remove, modify and regulate DNA for therapeutic, agricultural, and diagnostic applications. For additional information, please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

For more information:

Matthew Kane  
Chief Executive Officer  
Precision BioSciences, Inc.  
919-314-5512